RxDoctor Payments Data

Haklai Lau, MD

Internal Medicine · New Britain, CTNPI 1730136631

Payments from drug & device makers

$1,958in general payments, 2019–2025

Across 86 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hydrofera LLC$704
  • Smith+Nephew$573
  • KCI USA, Inc.$181
  • Tactile Systems Technology Inc$159
  • Organogenesis Inc.$68
  • Urgo Medical North America, LLC$48
  • plus $224 from 9 others

What the payments were for

  • Food & beverage$1,958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,958 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$271,062
Medicare patients
594
Services billed
4,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.26$95,265
Ammonium Lactate66$1,722
Triamcinolone Acetonide102$1,171
Metronidazole27$883
Cefadroxil76$738
Gentamicin Sulfate20$672
Timolol Maleate17$655
Doxycycline Hyclate31$386
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$382
Torsemide18$257
Minocycline Hcl14$197
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen42$158
Acetic Acid17$92
Levofloxacin17$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$573$95,26526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →